Search for Teva Pharmaceutical Industries Ltd and
  1. August 3, 2014

    Private equity eyes drug brands purchase

    Private equity groups are exploring a $10bn plan to buy hundreds of older drug brands from GlaxoSmithKline and Sanofi and...

  2. July 14, 2014

    Teva faces fresh shareholder showdown over management structure

    Teva is facing a fresh confrontation with shareholders after an activist investor accused the drugmaker of reneging on...

  1. July 9, 2014

    European regulators fine Servier of France

    European regulators have fined Servier of France and several other drugmakers €428m for blocking the introduction of cheaper...

  2. June 15, 2014

    Women in Business – Shira Kaplan, MBA student

    Shira Kaplan is an MBA student currently studying on the part-time programme at the University of St Gallen in Switzerland...

  3. May 23, 2014

    Teva: optimism, unfortunately

    Value investing in one tweet: when the worst-case scenario is for sale at fair value, buy it. The primary US patent on the...

  4. May 1, 2014

    Pharma deals reach new level of intensity

    Pfizer wants to buy AstraZeneca, which has been linked with a move for Shire, which is reportedly wanted by Allergan, which...

  5. January 23, 2014

    Teva seeks experience in board shake-up

    Teva has bowed to pressure from activist shareholders, saying it plans to slim down its board and recruit more directors...

  6. January 10, 2014

    Letter from Lex: a new beginning

    Happy Friday, readers. The first week with a new Head of Lex in the London office – an American, no less – is almost past...

  7. January 9, 2014

    Teva names Vigodman as chief executive

    Teva of Israel has sought to draw a line under months of turmoil at the world’s largest generic drugmaker by naming Erez...

  8. January 6, 2014

    Teva: in need of a shot

    The board of Teva Pharmaceuticals is a brains trust of scientific and medical knowledge. Shame that so few of its 16 members...

  9. January 6, 2014

    Teva activist investor backs nomination of Erez Vigodman as chief

    A leading activist shareholder in Teva has lent his support to the proposed nomination of one of the directors of the...

  10. December 29, 2013

    Accusations of insularity and interference haunt the Teva board

    Even by the standards of the regular leaks of sensitive corporate material from Teva, images on Israeli television last...

  11. December 29, 2013

    Teva shareholders press for boardroom shake up

    Leading shareholders in Teva, the world’s largest generic medicines company, are stepping up pressure for a boardroom shake...

  12. December 6, 2013

    How time and focus give non-executives extra oomph

    Hands-off directors and troubled banks seem to go hand in hand – or at least they have this decade. Sir David Walker’s...

  13. December 4, 2013

    Teva interim chief in favour of board diversity

    The interim chief executive of Teva has said he would welcome a more diversified board of directors as the governance of the...

  14. October 31, 2013

    Teva chief leaves as drugmaker struggles to take its medicine

    Wanted: chief executive with global vision, ideas for developing new medicines, experience in cost-cutting, ability to cope...

  15. October 30, 2013

    Teva: a mess, but priced right

    In moments of crisis, leaders say things that are not true. Everyone accepts this. Here, for example, is how Phillip Frost,...

  16. October 30, 2013

    Teva chief executive to step down amid boardroom tensions

    The head of the world’s largest generic drugs company is to step down, less than two years after taking the job in an effort...

  17. October 13, 2013

    Teva: turnabout

    Nostalgia for the financial crisis is rare. But for Teva Pharmaceuticals, the great crash is the good old days. From the...

  18. October 10, 2013

    Drugmaker Teva to cut workforce by 10%

    Teva, the world’s largest generic drugs maker, will sharply reduce its workforce next year as part of intensified...

  19. July 1, 2013

    Drugmakers: binding agents

    Big pharma and generic drugmakers are often at loggerheads. But they may need each other more than they care to admit. Aspen...

  20. June 12, 2013

    Teva and Sun Pharma fined $2.15bn for patent breach

    Generic drug makers Teva and Sun Pharma will pay $2.15bn to Pfizer and Takeda to settle a long-running patent dispute in the...

  21. April 28, 2013

    Teva discovers sophisticated fakes of popular drug

    Leading generic drugmakers are stepping up quality inspections in Europe after unearthing a sophisticated counterfeiting...

  22. December 5, 2012

    Drugs groups aim to halve cost of trials

    Two leading pharmaceutical companies aim to halve the costs of running clinical trials within five years, as they seek to...

  23. November 30, 2012

    Teva restructuring beckons

    Teva, the world’s largest generic drugs company, unveiled 2013 sales and earnings guidance below market expectations,...

  24. October 30, 2012

    Bayer – vitamin A to Z

    Move over pharmaceuticals. Here come “nutraceuticals”. Bayer on Tuesday said it would pay $1.2bn for Schiff Nutrition...

  25. August 14, 2012

    AstraZeneca signs Nexium deal with Pfizer

    AstraZeneca raised its full-year earnings expectations after signing a deal to allow Pfizer the future rights to market an...

  26. August 1, 2012

    Shire beats expectations with ADHD drugs

    Shares in Shire Pharmaceuticals clawed back some of their recent losses after stronger sales of its treatments for attention...

  27. June 25, 2012

    Shire shares slump as rival drug approved

    More than £1bn was wiped from Shire’s market capitalisation on Monday after the US Food and Drug Administration widened the...

  28. June 6, 2012

    US regulator calls for action on fake drugs

    Laws to combat counterfeit drug trafficking are toothless and need to be toughened, Margaret Hamburg, commissioner of the US...

  29. May 9, 2012

    Teva sales disappoint on chief’s exit

    Restructuring costs, exchange rate changes and sluggish business in Europe pulled sales below market expectations at Teva,...

  30. April 29, 2012

    Teva warns over generic drug price cuts

    Government price cuts on medicines that have come off patent risk creating shortages that will threaten patients’ lives, the...

  31. April 26, 2012

    Watson / Actavis: a generic drug cocktail

    Happy pills all around. The market is delighted by Watson Pharmaceuticals’ €4.5bn acquisition of Switzerland’s Actavis....

  32. March 21, 2012

    Watson in talks to acquire Actavis

    Watson Pharmaceuticals, the US generic drugmaker, is in talks to acquire Actavis in a deal that could value it Swiss rival...

  33. March 8, 2012

    Generic drugmakers: a dose of realism

    Generic drug companies have long salivated over the arrival of 2012. Lexapro, an anti-depressant medication, loses patent...

  34. January 9, 2012

    News anchor shakes up Israeli politics

    Israel’s political scene is bracing itself for fresh upheaval after Yair Lapid, one of the country’s best-known news anchors...

  35. January 3, 2012

    Teva: ringing the changes

    It was time for a change at Teva. The Israeli drug company’s shares were among the best places to ride out the financial...

  36. FT Alphaville

    January 3, 2012

    Teva CEO to retire in May

    The chief executive of Teva Pharmaceutical Industries Ltd, Shlomo Yanai, is set to retire in May, the WSJ reports. Jeremy...

  37. January 2, 2012

    Yanai to quit as Teva chief executive

    Teva unexpectedly announced the retirement of its chief executive and the appointment of a doctor, a drug industry veteran,...

  38. December 7, 2011

    US blocks move to widen morning-after pill sales

    The Obama administration has overruled the US Food and Drug Administration’s recommendation to let young women buy the...

Search for Teva Pharmaceutical Industries Ltd and